# Safety and Impact of Baricitinib on Cell Surivival Pathways, HIV-1 Reservoir and Inflamation in People With HIV-1

> **NCT07028385** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia** · enrollment: 30 (estimated)

## Conditions studied

- HIV

## Interventions

- **DRUG:** Bariticinib 2 mg
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07028385
- **Lead sponsor:** Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-09-22
- **Primary completion:** 2026-04
- **Final completion:** 2026-07
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-02-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07028385

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07028385, "Safety and Impact of Baricitinib on Cell Surivival Pathways, HIV-1 Reservoir and Inflamation in People With HIV-1". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07028385. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*